NCT03274375CompletedPhase 2
Immunoadsorption Therapy in Managing NMDAR Antibodies Encephalitis
Prospective Assessment of Efficacy of Immunoadsorption Therapy in Managing Childhood NMDA-Receptor (NMDAR) Antibodies Encephalitis
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
The purpose of the study is to assess the efficacy of immunoadsorption therapy (IA) on improving the neurological status of severe pediatric anti-NMDAR encephalitis patients.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 24 Jul 2017
- Start date
- 23 Jun 2021
- Primary completion date
- 26 Oct 2023
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- NCT number
- NCT03274375
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 20
- From 23 Jun 2021 to the primary completion date, 26 Oct 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Autoimmune encephalitis without NMDAR antibodies
- Contraindication to perform IA therapy :
- Clinical conditions that prohibit transitory volume changes
- Indications that prohibit anticoagulation using Heparin and/or ACD-A solutions
- History of hypercoagulability
- Generalized viral, bacterial and/or mycotic infections
- Severe immune deficiencies (e.g. AIDS)
- Suspected allergies against sheep antibodies or agarose
Other
- PCPCS and mRS scores ≥ 3 before first symptoms
- Contraindication to perform central vascular access
- Pregnancy, breastfeeding or absence of effective contraception (including abstinence) in a pubertal patient.
Who the study is looking for
- Age: 0-18 years inclusive
- Autoimmune encephalitis with positive anti-NMDAR antibodies in CSF (definite anti-NMDAR encephalitis according to Graus's criteria (Graus et al., 2016).
- PCPCS and mRS at 4 or over at the inclusion after first line therapy (steroids and/or IgIV) when Rituximab therapy is warranted
- Parents or legal guardians signed the Informed consent form
- Social insurance affiliation
Age in the registry: - to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hopital Necker Enfants Malades Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.